

10/629,975  
Lycod Search  
6/28/07

d his

(FILE 'HOME' ENTERED AT 13:55:41 ON 28 JUN 2007)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 13:56:08 ON 28 JUN 2007

L1 18442 S (ULCERATIVE COLITIS) AND TREATMENT  
L2 23 S L1 AND LACTOFERRIN?  
L3 17 DUPLICATE REMOVE L2 (6 DUPLICATES REMOVED)  
L4 7 S L3 AND PD<2001  
L5 551 S L1 AND MONITOR?  
L6 225 S L5 AND PD<2001  
L7 133 DUPLICATE REMOVE L6 (92 DUPLICATES REMOVED)  
L8 72 S (NEUTROPHIL DERIVED PROTEIN)  
L9 0 S L8 AND L7  
L10 7 S L8 AND IBD?  
L11 7 DUPLICATE REMOVE L10 (0 DUPLICATES REMOVED)  
L12 0 S L11 AND PD<2001  
L13 6 S L8 AND TREATMENT  
L14 1 S L8 AND MONITOR?  
L15 17 S L8 AND LACTOFERRIN?  
L16 8 DUPLICATE REMOVE L15 (9 DUPLICATES REMOVED)  
L17 0 S CALPROTEIN AND TREATMENT?  
L18 199 S CALPROTECTIN AND TREATMENT  
L19 59 S L18 AND COLITIS?  
L20 35 DUPLICATE REMOVE L19 (24 DUPLICATES REMOVED)  
L21 1 S L20 AND PD<2001  
L22 36 S L18 AND IBD  
L23 20 DUPLICATE REMOVE L22 (16 DUPLICATES REMOVED)  
L24 0 S L23 AND PD<2001  
L25 4891 S IBD AND TREATMENT  
L26 1413 S L25 AND PD<2001  
L27 797 DUPLICATE REMOVE L26 (616 DUPLICATES REMOVED)  
L28 26 S L27 AND MONITOR?  
L29 2 S L28 AND NEUTROPHIL?  
L30 468 S (ANTINEUTROPHIL ANTIBOD?)  
L31 2 S L30 AND LACTOFERRIN

=>

ANSWER 2 OF 3 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AN 1999322801 EMBASE

TI Faecal parameters in the assessment of activity in inflammatory bowel disease.

AU Van der Sluys Veer A.; Biemond I.; Verspaget H.W.; Lamers C.B.H.W.

CS A. Van der Sluys Veer, Dept of Gastroenterol. and Hepatol., Leiden University Medical Center, Building 1, PO Box 9600, C4-PNL-2300 RC Leiden, Netherlands

SO Scandinavian Journal of Gastroenterology, Supplement, (1999)  
Vol. 33, No. 230, pp. 106-110. .

Refs: 55

ISSN: 0085-5928 CODEN: SJGSB8

CY Norway

DT Journal; Article

FS 005 General Pathology and Pathological Anatomy

029 Clinical Biochemistry

037 Drug Literature Index

048 Gastroenterology

LA English

SL English

ED Entered STN: 30 Sep 1999

Last Updated on STN: 30 Sep 1999

AB Background: Determination of inflammatory activity is helpful when assessing the efficacy of drugs in therapeutic trials and in facilitating management of individual patients with inflammatory bowel disease (IBD). Faecal parameters have been hypothesized to be more specific than non-faecal measurements in the assessment of intestinal inflammation. Methods: Review of the literature on faecal measurements in IBD. Results and conclusions: Leakage of various proteins and leukocyte products into the intestinal lumen can be assessed and quantified in stool specimens and serve as a measurement of inflammatory activity. Several of these faecal parameters are raised in patients with IBD. There is a considerable overlap between patients with active and those with inactive disease, however, and the correlation of the faecal parameters with disease activity indices is often low. The value of  $\alpha$ -apprx.1-antitrypsin measurement in faeces in the assessment of intestinal inflammation has been well established. Further studies in patients with IBD are needed to determine whether other faecal parameters, such as lactoferrin, tumour necrosis factor  $\alpha$ , PMN-elastase, lysozyme, leucocyte esterase, immunoglobulin A, among others, are more accurate or cost-effective than measurement of  $\alpha$ -apprx.1-antitrypsin in the stools of such patients.

CT Medical Descriptors:

\*feces

\*enteritis: DI, diagnosis

\*enteritis: DT, drug therapy

\*Crohn disease: DI, diagnosis

\*Crohn disease: DT, drug therapy

\*ulcerative colitis: DI, diagnosis

\*ulcerative colitis: DT, drug therapy

gastrointestinal endoscopy

intestine biopsy

imaging

immunodiffusion

enzyme immunoassay

nephelometry

human

clinical trial

article

priority journal

Drug Descriptors:

\*alpha 1 antitrypsin: EC, endogenous compound

protein: EC, endogenous compound

lactoferrin: EC, endogenous compound  
tumor necrosis factor alpha: EC, endogenous compound  
leukocyte elastase: EC, endogenous compound  
lysozyme: EC, endogenous compound  
esterase: EC, endogenous compound  
immunoglobulin a: EC, endogenous compound  
barium  
methylprednisolone: CB, drug combination  
methylprednisolone: DT, drug therapy  
salazosulfapyridine: CB, drug combination  
salazosulfapyridine: DT, drug therapy  
hemoglobin: EC, endogenous compound  
indium 111

RN (alpha 1 antitrypsin) 9041-92-3; (protein) 67254-75-5; (  
lactoferrin) 55599-62-7; (leukocyte elastase) 109968-22-1;  
(lysozyme) 9001-63-2; (esterase) 9013-79-0; (barium) 7440-39-3;  
(methylprednisolone) 6923-42-8, 83-43-2; (salazosulfapyridine) 599-79-1;  
(hemoglobin) 9008-02-0; (indium 111) 15750-15-9

lactoferrin: EC, endogenous compound  
tumor necrosis factor alpha: EC, endogenous compound  
leukocyte elastase: EC, endogenous compound  
lysozyme: EC, endogenous compound  
esterase: EC, endogenous compound  
immunoglobulin a: EC, endogenous compound  
barium  
methylprednisolone: CB, drug combination  
methylprednisolone: DT, drug therapy  
salazosulfapyridine: CB, drug combination  
salazosulfapyridine: DT, drug therapy  
hemoglobin: EC, endogenous compound  
indium 111

RN (alpha 1 antitrypsin) 9041-92-3; (protein) 67254-75-5; (  
lactoferrin) 55599-62-7; (leukocyte elastase) 109968-22-1;  
(lysozyme) 9001-63-2; (esterase) 9013-79-0; (barium) 7440-39-3;  
(methylprednisolone) 6923-42-8, 83-43-2; (salazosulfapyridine) 599-79-1;  
(hemoglobin) 9008-02-0; (indium 111) 15750-15-9

ANSWER 2 OF 3 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights

reserved on STN

AN 2000365992 EMBASE

TI Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: Biological and clinical significance.

AU Caradonna L.; Amati L.; Magrone T.; Pellegrino N.M.; Jirillo E.; Caccavo D.

CS Dr. E. Jirillo, Immunologia, Policlinico, Piazza G. Cesare 4, 70124 Bari, Italy. jirillo@midim.uniba.it

SO Journal of Endotoxin Research, (2000) Vol. 6, No. 3, pp. 205-214.

Refs: 126

ISSN: 0968-0519 CODEN: JENREB

CY United Kingdom

DT Journal; General Review

FS 004 Microbiology

026 Immunology, Serology and Transplantation

030 Pharmacology

037 Drug Literature Index

048 Gastroenterology

LA English

SL English

ED Entered STN: 2 Nov 2000

Last Updated on STN: 2 Nov 2000

AB Ulcerative colitis (UC) and Crohn's disease (CD) [inflammatory bowel disease (IBD)] are both characterized by an exaggerated immune response at the gut associated lymphoreticular tissue level. Such an abnormal and dysregulated immune response may be directed against luminal and/or enteric bacterial antigens, as also supported by murine models of inflammatory bowel disease (IBD) caused by organisms such as *Citrobacter rodentium* and *Helicobacter hepaticus*. Bacterial endotoxins or lipopolysaccharides (LPS) have been detected in the plasma of IBD patients and an abnormal microflora and/or an increased permeability of the intestinal mucosa have been invoked as cofactors responsible for endotoxemia. At the same time, the evidence that phagocytosis and killing exerted by polymorphonuclear cells and monocytes and the T-cell dependent antibacterial activity are decreased in IBD patients may also explain the origin of LPS in these diseases. In IBD, pro-inflammatory cytokines and chemokines have been detected in elevated amounts in mucosal tissue and/or in peripheral blood, thus suggesting a monocyte/macrophage stimulation by enteric bacteria and/or their constituents (e.g. LPS). On these grounds, in experimental models and in human IBD, anti-cytokine monoclonal antibodies and interleukin receptor antagonists are under investigation for their capacity to neutralize the noxious effects of immune mediators. Finally, the administration of lactobacilli is beneficial in human IBD and, in murine colitis, this treatment leads to a normalization of intestinal flora, reducing the number of colonic mucosal adherent and translocated bacteria.

CT Medical Descriptors:

\*Enterobacteriaceae

\*enteritis

ulcerative colitis

Crohn disease

immune response

reticuloendothelial system

immunoregulation

*Citrobacter*

*Helicobacter hepaticus*

toxin analysis

intestine mucosa permeability

intestine flora

endotoxemia

phagocytosis

ANSWER 2 OF 3 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AN 2000365992 EMBASE

TI Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: Biological and clinical significance.

AU Caradonna L.; Amati L.; Magrone T.; Pellegrino N.M.; Jirillo E.; Caccavo D.

CS Dr. E. Jirillo, Immunologia, Policlinico, Piazza G. Cesare 4, 70124 Bari, Italy. jirillo@midim.uniba.it

SO Journal of Endotoxin Research, (2000) Vol. 6, No. 3, pp. 205-214.

Refs: 126

ISSN: 0968-0519 CODEN: JENREB

CY United Kingdom

DT Journal; General Review

FS 004 Microbiology

026 Immunology, Serology and Transplantation

030 Pharmacology

037 Drug Literature Index

048 Gastroenterology

LA English

SL English

ED Entered STN: 2 Nov 2000

Last Updated on STN: 2 Nov 2000

AB Ulcerative colitis (UC) and Crohn's disease (CD) [inflammatory bowel disease (IBD)] are both characterized by an exaggerated immune response at the gut associated lymphoreticular tissue level. Such an abnormal and dysregulated immune response may be directed against luminal and/or enteric bacterial antigens, as also supported by murine models of inflammatory bowel disease (IBD) caused by organisms such as *Citrobacter rodentium* and *Helicobacter hepaticus*. Bacterial endotoxins or lipopolysaccharides (LPS) have been detected in the plasma of IBD patients and an abnormal microflora and/or an increased permeability of the intestinal mucosa have been invoked as cofactors responsible for endotoxemia. At the same time, the evidence that phagocytosis and killing exerted by polymorphonuclear cells and monocytes and the T-cell dependent antibacterial activity are decreased in IBD patients may also explain the origin of LPS in these diseases. In IBD, pro-inflammatory cytokines and chemokines have been detected in elevated amounts in mucosal tissue and/or in peripheral blood, thus suggesting a monocyte/macrophage stimulation by enteric bacteria and/or their constituents (e.g. LPS). On these grounds, in experimental models and in human IBD, anti-cytokine monoclonal antibodies and interleukin receptor antagonists are under investigation for their capacity to neutralize the noxious effects of immune mediators. Finally, the administration of lactobacilli is beneficial in human IBD and, in murine colitis, this treatment leads to a normalization of intestinal flora, reducing the number of colonic mucosal adherent and translocated bacteria.

CT Medical Descriptors:

\*Enterobacteriaceae

\*enteritis

ulcerative colitis

Crohn disease

immune response

reticuloendothelial system

immunoregulation

*Citrobacter*

*Helicobacter hepaticus*

toxin analysis

intestine mucosa permeability

intestine flora

endotoxemia

phagocytosis

polymorphonuclear cell  
monocyte  
T lymphocyte  
antibacterial activity  
macrophage  
cell stimulation  
Lactobacillus  
bacterial translocation  
bacterium adherence  
human  
nonhuman  
mouse  
animal experiment  
animal model  
controlled study  
human cell  
animal cell  
review

Drug Descriptors:

\*bacterium lipopolysaccharide: EC, endogenous compound  
\*cytokine: EC, endogenous compound  
bacterial antigen: EC, endogenous compound  
endotoxin: EC, endogenous compound  
chemokine: EC, endogenous compound  
interleukin receptor: EC, endogenous compound  
interleukin 10: EC, endogenous compound  
interleukin 12: EC, endogenous compound  
gamma interferon: EC, endogenous compound  
CD4 antigen: EC, endogenous compound  
CD8 antigen: EC, endogenous compound  
tumor necrosis factor alpha: EC, endogenous compound  
interleukin 8: EC, endogenous compound  
monocyte chemotactic protein 1: EC, endogenous compound  
granulocyte macrophage colony stimulating factor: EC, endogenous compound  
butyric acid: EC, endogenous compound  
interleukin 1beta: EC, endogenous compound  
immunoglobulin A: EC, endogenous compound  
lactoferrin: EC, endogenous compound  
glyceraldehyde 3 phosphate: EC, endogenous compound  
nitric oxide: EC, endogenous compound  
monoclonal antibody: PD, pharmacology  
monoclonal antibody ca2: PD, pharmacology  
tumor necrosis factor alpha antibody: PD, pharmacology  
cytokine antibody: PD, pharmacology  
CD45 antigen: EC, endogenous compound  
recombinant interleukin 10: PD, pharmacology  
placebo  
antisense oligonucleotide: PD, pharmacology  
immunoglobulin enhancer binding protein: EC, endogenous compound  
unclassified drug

RN (interleukin 12) 138415-13-1; (gamma interferon) 82115-62-6; (interleukin 8) 114308-91-7; (butyric acid) 107-92-6, 156-54-7, 461-55-2; (lactoferrin) 55599-62-7; (glyceraldehyde 3 phosphate) 142-10-9; (nitric oxide) 10102-43-9

polymorphonuclear cell  
monocyte  
T lymphocyte  
antibacterial activity  
macrophage  
cell stimulation  
Lactobacillus  
bacterial translocation  
bacterium adherence  
human  
nonhuman  
mouse  
animal experiment  
animal model  
controlled study  
human cell  
animal cell  
review

Drug Descriptors:

\*bacterium lipopolysaccharide: EC, endogenous compound  
\*cytokine: EC, endogenous compound  
bacterial antigen: EC, endogenous compound  
endotoxin: EC, endogenous compound  
chemokine: EC, endogenous compound  
interleukin receptor: EC, endogenous compound  
interleukin 10: EC, endogenous compound  
interleukin 12: EC, endogenous compound  
gamma interferon: EC, endogenous compound  
CD4 antigen: EC, endogenous compound  
CD8 antigen: EC, endogenous compound  
tumor necrosis factor alpha: EC, endogenous compound  
interleukin 8: EC, endogenous compound  
monocyte chemotactic protein 1: EC, endogenous compound  
granulocyte macrophage colony stimulating factor: EC, endogenous compound  
butyric acid: EC, endogenous compound  
interleukin 1beta: EC, endogenous compound  
immunoglobulin A: EC, endogenous compound  
lactoferrin: EC, endogenous compound  
glyceraldehyde 3 phosphate: EC, endogenous compound  
nitric oxide: EC, endogenous compound  
monoclonal antibody: PD, pharmacology  
monoclonal antibody ca2: PD, pharmacology  
tumor necrosis factor alpha antibody: PD, pharmacology  
cytokine antibody: PD, pharmacology  
CD45 antigen: EC, endogenous compound  
recombinant interleukin 10: PD, pharmacology  
placebo  
antisense oligonucleotide: PD, pharmacology  
immunoglobulin enhancer binding protein: EC, endogenous compound  
unclassified drug

RN (interleukin 12) 138415-13-1; (gamma interferon) 82115-62-6; (interleukin 8) 114308-91-7; (butyric acid) 107-92-6, 156-54-7, 461-55-2; (lactoferrin) 55599-62-7; (glyceraldehyde 3 phosphate) 142-10-9; (nitric oxide) 10102-43-9



ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:803924 CAPLUS

DN 128:60253

ED Entered STN: 25 Dec 1997

TI Measurement of fecal lactoferrin for diagnosis on pediatric gastrointestinal disease

AU Tabata, Kazue; Matsuse, Ryoichi; Uchida, Kazuo; Amemoto, Kanji

CS Kyoto Med. Sci. Lab., Kyoto, 612, Japan

SO Rinsho Byori (1997), 45(12), 1201-1203

CODEN: RBYOAI; ISSN: 0047-1860

PB Rinsho Byori Kankokai

DT Journal

LA Japanese

CC 14-7 (Mammalian Pathological Biochemistry)

AB The fecal proteins in blood and granules related with inflammation have been measured to examine the conditions of inflammation in inflammation in inflammatory bowel disease (IBD). To noninvasively examine the conditions in pediatric patients with various gastrointestinal diseases, we evaluated the usefulness of measuring the concentration of fecal lactoferrin (Lf), which is the specific granule component in neutrophils. Lf was measured by ELISA in patients with infectious enteritis (E), Henoch Schonlein purpura (HSP), and ulcerative colitis (UC), and in control subjects. The fecal Lf levels were significantly higher in patients with E, HSP, and UC than in control subjects. The fecal Lf levels were significantly increased in not only patients with bacterial but also those with viral gastroenteritis. These findings suggest that the measurement of fecal Lf concentration is useful for noninvasive

monitoring of the disease activity in pediatric patients with gastrointestinal disease and the activities of neutrophils elevate in patients with viral infectious enteritis.

ST lactoferrin feces child gastrointestinal disease diagnosis;  
inflammatory bowel disease feces lactoferrin child

IT Purpura (disease)  
(Henoch-Schoenlein's; usefulness of measurement of fecal  
lactoferrin in diagnosis of pediatric gastrointestinal disease)

IT Development, mammalian postnatal  
(child; usefulness of measurement of fecal lactoferrin in  
diagnosis of pediatric gastrointestinal disease)

IT Intestine, disease  
(enteritis, infectious; usefulness of measurement of fecal  
lactoferrin in diagnosis of pediatric gastrointestinal disease)

IT Intestine, disease  
(inflammatory; usefulness of measurement of fecal lactoferrin  
in diagnosis of pediatric gastrointestinal disease)

IT Intestine, disease  
(ulcerative colitis; usefulness of measurement of fecal  
lactoferrin in diagnosis of pediatric gastrointestinal disease)

IT Diagnosis

Feces  
(usefulness of measurement of fecal lactoferrin in diagnosis  
of pediatric gastrointestinal disease)

IT Lactoferrins

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); THU  
(Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)  
(usefulness of measurement of fecal lactoferrin in diagnosis  
of pediatric gastrointestinal disease)

=>

AN 1997:803924 CAPLUS

DN 128:60253

ED Entered STN: 25 Dec 1997

TI Measurement of fecal lactoferrin for diagnosis on pediatric gastrointestinal disease

AU Tabata, Kazue; Matsuse, Ryoichi; Uchida, Kazuo; Amemoto, Kanji

CS Kyoto Med. Sci. Lab., Kyoto, 612, Japan

SO Rinsho Byori (1997), 45(12), 1201-1203

CODEN: RBYOAI; ISSN: 0047-1860

PB Rinsho Byori Kankokai

DT Journal

LA Japanese

CC 14-7 (Mammalian Pathological Biochemistry)

AB The fecal proteins in blood and granules related with inflammation have been measured to examine the conditions of inflammation in inflammation in inflammatory bowel disease (IBD). To noninvasively examine the conditions in pediatric patients with various gastrointestinal diseases, we evaluated the usefulness of measuring the concentration of fecal lactoferrin (Lf), which is the specific granule component in neutrophils. Lf was measured by ELISA in patients with infectious enteritis (E), Henoch Schonlein purpura (HSP), and ulcerative colitis (UC), and in control subjects. The fecal Lf levels were significantly higher in patients with E, HSP, and UC than in control subjects. The fecal Lf levels were significantly increased in not only patients with bacterial but also those with viral gastroenteritis. These findings suggest that the measurement of fecal Lf concentration is useful for noninvasive

monitoring of the disease activity in pediatric patients with gastrointestinal disease and the activities of neutrophils elevate in patients with viral infectious enteritis.

ST lactoferrin feces child gastrointestinal disease diagnosis; inflammatory bowel disease feces lactoferrin child

IT Purpura (disease)  
(Henoch-Schoenlein's; usefulness of measurement of fecal lactoferrin in diagnosis of pediatric gastrointestinal disease)

IT Development, mammalian postnatal  
(child; usefulness of measurement of fecal lactoferrin in diagnosis of pediatric gastrointestinal disease)

IT Intestine, disease  
(enteritis, infectious; usefulness of measurement of fecal lactoferrin in diagnosis of pediatric gastrointestinal disease)

IT Intestine, disease  
(inflammatory; usefulness of measurement of fecal lactoferrin in diagnosis of pediatric gastrointestinal disease)

IT Intestine, disease  
(ulcerative colitis; usefulness of measurement of fecal lactoferrin in diagnosis of pediatric gastrointestinal disease)

IT Diagnosis  
Feces  
(usefulness of measurement of fecal lactoferrin in diagnosis of pediatric gastrointestinal disease)

IT Lactoferrins  
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)  
(usefulness of measurement of fecal lactoferrin in diagnosis of pediatric gastrointestinal disease)

ANSWER 2 OF 2 MEDLINE on STN  
AN 94127317 MEDLINE  
DN PubMed ID: 8296668  
TI Antineutrophil antibodies in inflammatory bowel  
disease recognize different antigens.  
AU Mulder A H; Broekroelofs J; Horst G; Limburg P C; Nelis G F; Kallenberg C  
G  
CS Dept. of Clinical Immunology, University Hospital Groningen, The  
Netherlands.  
SO Advances in experimental medicine and biology, (1993) Vol. 336, pp.  
519-22.  
Journal code: 0121103. ISSN: 0065-2598.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199403  
ED Entered STN: 14 Mar 1994  
Last Updated on STN: 3 Feb 1997  
Entered Medline: 3 Mar 1994  
AB Anti-neutrophil cytoplasmic antibodies (ANCA) were observed in 31 out of  
68 sera (45%) from Ulcerative Colitis (UC) patients and in 13 out of 38  
Crohn's Disease (CD) sera (34%). The presence of ANCA was not related to  
disease activity, nor to the localization of the disease manifestations.  
By Western Blotting ANCA showed reactivity with either lactoferrin  
, polypeptides occurring as a doublet of 66/67 kD MW, or polypeptides  
occurring as a doublet of 63/54 kD MW.  
CT Antibodies, Antineutrophil Cytoplasmic  
\*Antibody Specificity  
Autoantibodies: BL, blood  
\*Autoantibodies: IM, immunology  
\*Autoantigens: IM, immunology  
Blotting, Western  
Colitis, Ulcerative: IM, immunology  
Crohn Disease: IM, immunology  
Humans  
Immunoglobulin G: BL, blood  
\*Immunoglobulin G: IM, immunology  
\*Inflammatory Bowel Diseases: IM, immunology  
Lactoferrin: IM, immunology  
CN 0 (Antibodies, Antineutrophil Cytoplasmic); 0 (Autoantibodies); 0  
(Autoantigens); 0 (Immunoglobulin G); 0 (Lactoferrin)

=>

ANSWER 2 OF 2 MEDLINE on STN

AN 94127317 MEDLINE

DN PubMed ID: 8296668

TI Antineutrophil antibodies in inflammatory bowel disease recognize different antigens.

AU Mulder A H; Broekroelofs J; Horst G; Limburg P C; Nelis G F; Kallenberg C G

CS Dept. of Clinical Immunology, University Hospital Groningen, The Netherlands.

SO Advances in experimental medicine and biology, (1993) Vol. 336, pp. 519-22.

Journal code: 0121103. ISSN: 0065-2598.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199403

ED Entered STN: 14 Mar 1994

Last Updated on STN: 3 Feb 1997

Entered Medline: 3 Mar 1994

AB Anti-neutrophil cytoplasmic antibodies (ANCA) were observed in 31 out of 68 sera (45%) from Ulcerative Colitis (UC) patients and in 13 out of 38 Crohn's Disease (CD) sera (34%). The presence of ANCA was not related to disease activity, nor to the localization of the disease manifestations. By Western Blotting ANCA showed reactivity with either lactoferrin, polypeptides occurring as a doublet of 66/67 kD MW, or polypeptides occurring as a doublet of 63/54 kD MW.

CT Antibodies, Antineutrophil Cytoplasmic

\*Antibody Specificity

Autoantibodies: BL, blood

\*Autoantibodies: IM, immunology

\*Autoantigens: IM, immunology

Blotting, Western

Colitis, Ulcerative: IM, immunology

Crohn Disease: IM, immunology

Humans

Immunoglobulin G: BL, blood

\*Immunoglobulin G: IM, immunology

\*Inflammatory Bowel Diseases: IM, immunology

Lactoferrin: IM, immunology

CN 0 (Antibodies, Antineutrophil Cytoplasmic); 0 (Autoantibodies); 0 (Autoantigens); 0 (Immunoglobulin G); 0 (Lactoferrin)

=>

d his

(FILE 'HOME' ENTERED AT 13:55:41 ON 28 JUN 2007)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 13:56:08 ON 28 JUN 2007

L1 18442 S (ULCERATIVE COLITIS) AND TREATMENT  
L2 23 S L1 AND LACTOFERRIN?  
L3 17 DUPLICATE REMOVE L2 (6 DUPLICATES REMOVED)  
L4 7 S L3 AND PD<2001  
L5 551 S L1 AND MONITOR?  
L6 225 S L5 AND PD<2001  
L7 133 DUPLICATE REMOVE L6 (92 DUPLICATES REMOVED)  
L8 72 S (NEUTROPHIL DERIVED PROTEIN)  
L9 0 S L8 AND L7  
L10 7 S L8 AND IBD?  
L11 7 DUPLICATE REMOVE L10 (0 DUPLICATES REMOVED)  
L12 0 S L11 AND PD<2001  
L13 6 S L8 AND TREATMENT  
L14 1 S L8 AND MONITOR?  
L15 17 S L8 AND LACTOFERRIN?  
L16 8 DUPLICATE REMOVE L15 (9 DUPLICATES REMOVED)  
L17 0 S CALPROTEIN AND TREATMENT?  
L18 199 S CALPROTECTIN AND TREATMENT  
L19 59 S L18 AND COLITIS?  
L20 35 DUPLICATE REMOVE L19 (24 DUPLICATES REMOVED)  
L21 1 S L20 AND PD<2001  
L22 36 S L18 AND IBD  
L23 20 DUPLICATE REMOVE L22 (16 DUPLICATES REMOVED)  
L24 0 S L23 AND PD<2001  
L25 4891 S IBD AND TREATMENT  
L26 1413 S L25 AND PD<2001  
L27 797 DUPLICATE REMOVE L26 (616 DUPLICATES REMOVED)  
L28 26 S L27 AND MONITOR?  
L29 2 S L28 AND NEUTROPHIL?  
L30 468 S (ANTINEUTROPHIL ANTIBOD?)  
L31 2 S L30 AND LACTOFERRIN

=>

ANSWER 9 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:662373 CAPLUS  
DN 125:346231  
ED Entered STN: 09 Nov 1996  
TI **Linear** calibration in quantitative chemical analysis  
AU Hoeyer, Boy  
CS Kemisk Institut, Aarhus Universitet, Den.  
SO Dansk Kemi (1994), 75(5), 26-28  
CODEN: DAKEAT; ISSN: 0011-6335  
PB Teknisk Forlag  
DT Journal; General Review  
LA Danish  
CC 79-0 (Inorganic Analytical Chemistry)  
Section cross-reference(s): 80  
AB A **review** with 5 refs. The theory of **linear** calibration by least-square method is summarized, and a description is presented of how maximum precision can be obtained of concns. determined by the calibration. The article describes 2 calibration methods: (1) calibration from a **std. curve** measured from sep. standard solns., and (2) standard addition in which all measurements are conducted in the sample, and discusses limitations and some practical aspects of the 2 methods.  
ST **review linear** calibration quant analysis; statistical analysis **linear** calibration **review**; least squares calibration analysis **review**  
IT Statistics and Statistical analysis  
(least-squares, **linear** calibration in quant. chemical anal.)  
IT Calibration  
(**linear**, in quant. chemical anal.)  
IT Analysis  
(quant., **linear** calibration in)

ANSWER 1 OF 3 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN  
AN 1999:253375 BIOSIS  
DN PREV199900253375  
TI Fecal lactoferrin test (FLT) in the diagnosis of  
diarrhea in children.  
AU Cuadros, J. A. [Reprint author]; Gomez-Herruz, P. [Reprint author];  
Gonzalez-Palacios, R. [Reprint author]; Romanyk, J. [Reprint author];  
Beltran, M. [Reprint author]  
CS Hosp. Principe de Asturias, Alcala de Henares, Madrid, Spain  
SO Abstracts of the Interscience Conference on Antimicrobial Agents and  
Chemotherapy, (1998) Vol. 38, pp. 563. print.  
Meeting Info.: 38th Interscience Conference on Antimicrobial Agents and  
Chemotherapy. San Diego, California, USA. September 24-27, 1998. American  
Society for Microbiology.  
DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
Conference; (Meeting Poster)  
LA English  
ED Entered STN: 2 Jul 1999  
Last Updated on STN: 2 Jul 1999  
CC Digestive system - General and methods 14001  
Biochemistry studies - General 10060  
Pediatrics - 25000  
Chemotherapy - General, methods and metabolism 38502  
Medical and clinical microbiology - General and methods 36001  
General biology - Symposia, transactions and proceedings 00520  
IT Major Concepts  
Gastroenterology (Human Medicine, Medical Sciences); Pediatrics (Human  
Medicine, Medical Sciences)  
IT Parts, Structures, & Systems of Organisms  
leukocytes: blood and lymphatics, immune system  
IT Diseases  
diarrhea: digestive system disease  
Diarrhea (MeSH)  
IT Chemicals & Biochemicals  
lactoferrin  
IT Methods & Equipment  
antibiotic treatment: therapeutic method; fecal  
lactoferrin test: diagnostic method; microscopy: microscopy  
method  
IT Miscellaneous Descriptors  
Meeting Abstract; Meeting Poster  
ORGN Classifier  
Hominidae 86215  
Super Taxa  
Primates; Mammalia; Vertebrata; Chordata; Animalia  
Organism Name  
human: child, patient  
Taxa Notes  
Animals, Chordates, Humans, Mammals, Primates, Vertebrates

ANSWER 1 OF 3 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

AN 1999:253375 BIOSIS

DN PREV199900253375

TI Fecal lactoferrin test (FLT) in the diagnosis of  
diarrhea in children.

AU Cuadros, J. A. [Reprint author]; Gomez-Herruz, P. [Reprint author];  
Gonzalez-Palacios, R. [Reprint author]; Romanyk, J. [Reprint author];  
Beltran, M. [Reprint author]

CS Hosp. Principe de Asturias, Alcala de Henares, Madrid, Spain

SO Abstracts of the Interscience Conference on Antimicrobial Agents and  
Chemotherapy, (1998) Vol. 38, pp. 563. print.  
Meeting Info.: 38th Interscience Conference on Antimicrobial Agents and  
Chemotherapy. San Diego, California, USA. September 24-27, 1998. American  
Society for Microbiology.

DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
Conference; (Meeting Poster)

LA English

ED Entered STN: 2 Jul 1999  
Last Updated on STN: 2 Jul 1999

CC Digestive system - General and methods 14001  
Biochemistry studies - General 10060  
Pediatrics - 25000  
Chemotherapy - General, methods and metabolism 38502  
Medical and clinical microbiology - General and methods 36001  
General biology - Symposia, transactions and proceedings 00520

IT Major Concepts  
Gastroenterology (Human Medicine, Medical Sciences); Pediatrics (Human  
Medicine, Medical Sciences)

IT Parts, Structures, & Systems of Organisms  
leukocytes: blood and lymphatics, immune system

IT Diseases  
diarrhea: digestive system disease  
Diarrhea (MeSH)

IT Chemicals & Biochemicals  
lactoferrin

IT Methods & Equipment  
antibiotic treatment: therapeutic method; fecal  
lactoferrin test: diagnostic method; microscopy: microscopy  
method

IT Miscellaneous Descriptors  
Meeting Abstract; Meeting Poster

ORGN Classifier  
Hominidae 86215  
Super Taxa  
Primates; Mammalia; Vertebrata; Chordata; Animalia  
Organism Name  
human: child, patient  
Taxa Notes  
Animals, Chordates, Humans, Mammals, Primates, Vertebrates



reserved on STN

AN 1999322801 EMBASE

TI Faecal parameters in the assessment of activity in inflammatory bowel disease.

AU Van der Sluys Veer A.; Biemond I.; Verspaget H.W.; Lamers C.B.H.W.

CS A. Van der Sluys Veer, Dept of Gastroenterol. and Hepatol., Leiden University Medical Center, Building 1, PO Box 9600, C4-PNL-2300 RC Leiden, Netherlands

SO Scandinavian Journal of Gastroenterology, Supplement, (1999) Vol. 33, No. 230, pp. 106-110.

Refs: 55

ISSN: 0085-5928 CODEN: SJGSB8

CY Norway

DT Journal; Article

FS 005 General Pathology and Pathological Anatomy

029 Clinical Biochemistry

037 Drug Literature Index

048 Gastroenterology

LA English

SL English

ED Entered STN: 30 Sep 1999

Last Updated on STN: 30 Sep 1999

AB Background: Determination of inflammatory activity is helpful when assessing the efficacy of drugs in therapeutic trials and in facilitating management of individual patients with inflammatory bowel disease (IBD). Faecal parameters have been hypothesized to be more specific than non-faecal measurements in the assessment of intestinal inflammation. Methods: Review of the literature on faecal measurements in IBD. Results and conclusions: Leakage of various proteins and leukocyte products into the intestinal lumen can be assessed and quantified in stool specimens and serve as a measurement of inflammatory activity. Several of these faecal parameters are raised in patients with IBD. There is a considerable overlap between patients with active and those with inactive disease, however, and the correlation of the faecal parameters with disease activity indices is often low. The value of  $\alpha$ -apprx.1-antitrypsin measurement in faeces in the assessment of intestinal inflammation has been well established. Further studies in patients with IBD are needed to determine whether other faecal parameters, such as lactoferrin, tumour necrosis factor  $\alpha$ , PMN-elastase, lysozyme, leucocyte esterase, immunoglobulin A, among others, are more accurate or cost-effective than measurement of  $\alpha$ -apprx.1-antitrypsin in the stools of such patients.

CT Medical Descriptors:

\*feces

\*enteritis: DI, diagnosis

\*enteritis: DT, drug therapy

\*Crohn disease: DI, diagnosis

\*Crohn disease: DT, drug therapy

\*ulcerative colitis: DI, diagnosis

\*ulcerative colitis: DT, drug therapy

gastrointestinal endoscopy

intestine biopsy

imaging

immunodiffusion

enzyme immunoassay

nephelometry

human

clinical trial

article

priority journal

Drug Descriptors:

\*alpha 1 antitrypsin: EC, endogenous compound

protein: EC, endogenous compound

ANSWER 1 OF 2 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

AN 1997:392620 BIOSIS

DN PREV199799691823

TI Antineutrophil cytoplasmic antibodies in children with inflammatory bowel disease: Prevalence and diagnostic value.

AU Olives, Jean-Pierre [Reprint author]; Breton, Anne; Hugot, Jean-Pierre; Oksman, Francoise; Johannet, Catherine; Ghisolfi, Jacques; Navarro, Jean; Cezard, Jean-Pierre

CS Serv. Med. Infantile D, CHU Purpan, 31059 Toulouse Cedex, France

SO Journal of Pediatric Gastroenterology and Nutrition, (1997) Vol. 25, No. 2, pp. 142-148.

CODEN: JPGND6. ISSN: 0277-2116.

DT Article

LA English

ED Entered STN: 10 Sep 1997

Last Updated on STN: 10 Sep 1997

AB Background: Antineutrophil cytoplasmic antibodies (ANCA), particularly perinuclear ANCA (p-ANCA), have been found more frequently in sera from patients with ulcerative colitis (UC) than in sera from Crohn's disease (CD) or unclassified enterocolitis (UE) patients. This 2-center study examined sera from 102 pediatric patients with inflammatory bowel disease (IBD) to evaluate their diagnostic value and assess their relationship with disease features, distribution, activity and treatment. Methods: The serum ANCA of 102 children with IBD were measured: 33 UC; 64 CD and 5 UE with various disease locations and-degrees of activity. The mean age at the onset of symptoms was 10.7 years (1 to 16.3 years). Sera from 26 unaffected first degree relatives and 20 children without IBD were also investigated. ANCA were detected using indirect immunofluorescence of ethanol-fixed granulocytes. Results: There were ANCA in the sera of 24/33 children with UC (73%), 9/64 with CD (14%) and 4/5 with UE (80%). p-ANCA were more frequent than cytoplasmic-ANCA in positive sera: UC = 67%, CD = 57% and UE = 75%. The presence of ANCA was 73% sensitive and 81% specific for a diagnosis of UC, compared to other IBD (p lt 0.001). Three children with proved sclerosing cholangitis associated with UC were all positive. There was no link between ANCA-positive sera and disease activity, or other endoscopic or clinical criteria. ANCA were detected in 4/26 first degree relatives (15%) and in 1/20 control subjects (5%). Conclusions: Because of their sensitivity and specificity, ANCA may be helpful in the clinical assessment of patients with IBD, and especially those with UC. However, there is no link between the presence of p-ANCA and the site of UC or its activity, so that it cannot be used to monitor medical treatment or surgical indications.

CC Cytology - Human 02508

Clinical biochemistry - General methods and applications 10006

Biochemistry methods - Proteins, peptides and amino acids 10054

Biochemistry methods - Carbohydrates 10058

Biochemistry studies - Proteins, peptides and amino acids 10064

Biochemistry studies - Carbohydrates 10068

Pathology - Diagnostic 12504

Pathology - Inflammation and inflammatory disease 12508

Digestive system - Pathology 14006

Blood - Blood and lymph studies 15002

Blood - Lymphatic tissue and reticuloendothelial system 15008

Pediatrics - 25000

Immunology - General and methods 34502

Immunology - Immunopathology, tissue immunology 34508

IT Major Concepts

Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport and Circulation); Cell Biology; Clinical Chemistry (Allied Medical Sciences); Clinical Endocrinology (Human Medicine, Medical Sciences); Gastroenterology (Human Medicine, Medical Sciences); Immune System (Chemical Coordination and Homeostasis); Pathology; Pediatrics (Human Medicine, Medical Sciences)

AN 1997:392620 BIOSIS

DN PREV199799691823

TI Antineutrophil cytoplasmic antibodies in children with inflammatory bowel disease: Prevalence and diagnostic value.

AU Olives, Jean-Pierre [Reprint author]; Breton, Anne; Hugot, Jean-Pierre; Oksman, Francoise; Johannet, Catherine; Ghisolfi, Jacques; Navarro, Jean; Cezard, Jean-Pierre

CS Serv. Med. Infantile D, CHU Purpan, 31059 Toulouse Cedex, France

SO Journal of Pediatric Gastroenterology and Nutrition, (1997) Vol. 25, No. 2, pp. 142-148.

CODEN: JPGND6. ISSN: 0277-2116.

DT Article

LA English

ED Entered STN: 10 Sep 1997

Last Updated on STN: 10 Sep 1997

AB Background: Antineutrophil cytoplasmic antibodies (ANCA), particularly perinuclear ANCA (p-ANCA), have been found more frequently in sera from patients with ulcerative colitis (UC) than in sera from Crohn's disease (CD) or unclassified enterocolitis (UE) patients. This 2-center study examined sera from 102 pediatric patients with inflammatory bowel disease (IBD) to evaluate their diagnostic value and assess their relationship with disease features, distribution, activity and treatment. Methods: The serum ANCA of 102 children with IBD were measured: 33 UC, 64 CD and 5 UE with various disease locations and-degrees of activity. The mean age at the onset of symptoms was 10.7 years (1 to 16.3 years). Sera from 26 unaffected first degree relatives and 20 children without IBD were also investigated. ANCA were detected using indirect immunofluorescence of ethanol-fixed granulocytes. Results: There were ANCA in the sera of 24/33 children with UC (73%), 9/64 with CD (14%) and 4/5 with UE (80%). p-ANCA were more frequent than cytoplasmic-ANCA in positive sera: UC = 67%, CD = 57% and UE = 75%. The presence of ANCA was 73% sensitive and 81% specific for a diagnosis of UC, compared to other IBD (p lt 0.001). Three children with proved sclerosing cholangitis associated with UC were all positive. There was no link between ANCA-positive sera and disease activity, or other endoscopic or clinical criteria. ANCA were detected in 4/26 first degree relatives (15%) and in 1/20 control subjects (5%). Conclusions: Because of their sensitivity and specificity, ANCA may be helpful in the clinical assessment of patients with IBD, and especially those with UC. However, there is no link between the presence of p-ANCA and the site of UC or its activity, so that it cannot be used to monitor medical treatment or surgical indications.

CC Cytology - Human 02508

Clinical biochemistry - General methods and applications 10006

Biochemistry methods - Proteins, peptides and amino acids 10054

Biochemistry methods - Carbohydrates 10058

Biochemistry studies - Proteins, peptides and amino acids 10064

Biochemistry studies - Carbohydrates 10068

Pathology - Diagnostic 12504

Pathology - Inflammation and inflammatory disease 12508

Digestive system - Pathology 14006

Blood - Blood and lymph studies 15002

Blood - Lymphatic tissue and reticuloendothelial system 15008

Pediatrics - 25000

Immunology - General and methods 34502

Immunology - Immunopathology, tissue immunology 34508

IT Major Concepts

Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport and Circulation); Cell Biology; Clinical Chemistry (Allied Medical Sciences); Clinical Endocrinology (Human Medicine, Medical Sciences); Gastroenterology (Human Medicine, Medical Sciences); Immune System (Chemical Coordination and Homeostasis); Pathology; Pediatrics (Human Medicine, Medical Sciences)

IT Miscellaneous Descriptors

ANTINEUTROPHIL CYTOPLASMIC ANTIBODY; BLOOD AND LYMPHATICS; CHILD;  
CLINICAL IMMUNOLOGY; CROHN'S DISEASE; DIAGNOSTIC VALUE; DIGESTIVE  
SYSTEM DISEASE; GASTROENTEROLOGY; IMMUNE SYSTEM; IMMUNE SYSTEM DISEASE;  
INFLAMMATORY BOWEL DISEASE; NEUTROPHIL; PEDIATRICS;  
PREVALENCE; ULCERATIVE COLITIS

ORGN Classifier

Hominidae 86215

Super Taxa

Primates; Mammalia; Vertebrata; Chordata; Animalia

Organism Name

human

Taxa Notes

Animals, Chordates, Humans, Mammals, Primates, Vertebrates

IT Miscellaneous Descriptors

ANTINEUTROPHIL CYTOPLASMIC ANTIBODY; BLOOD AND LYMPHATICS; CHILD;  
CLINICAL IMMUNOLOGY; CROHN'S DISEASE; DIAGNOSTIC VALUE; DIGESTIVE  
SYSTEM DISEASE; GASTROENTEROLOGY; IMMUNE SYSTEM; IMMUNE SYSTEM DISEASE;  
INFLAMMATORY BOWEL DISEASE; NEUTROPHIL; PEDIATRICS;  
PREVALENCE; ULCERATIVE COLITIS

ORGN Classifier

Hominidae 86215

Super Taxa

Primates; Mammalia; Vertebrata; Chordata; Animalia

Organism Name

human

Taxa Notes

Animals, Chordates, Humans, Mammals, Primates, Vertebrates

L/Cook  
6/27/07



Application Number

Submit

IDS Flag Clearance for Application 10629975

IDS Information

Content	Mailroom Date	Entry Number	IDS Review	Last Modified	Reviewer
Update					